As the demand for increased speed in human clinical trial review, document production and delivery continues, Quorum recognizes the importance of maintaining, implementing and improving robust quality systems. Mr. Malafronte brings with him a wealth of knowledge and experience to help Quorum build upon its market leading innovations while maintaining strict adherence to outstanding regulatory compliance practices. "Mike brings to Quorum the expertise to insure that Quorum's performance remains consistent, reliable and on the cutting edge," explains Cami Gearhart, CEO.

Prior to joining Quorum Review IRB, Mr. Malafronte directed quality groups at Nastech Pharmaceuticals, ICOS Corporation, and Abbott Labs. "It is a pleasure to be heading up the Quality Management and Document Administration teams at Quorum Review," says Mr. Malafronte. "I'm very excited about the on-going work here at Quorum and the outstanding groups that I will direct. My experience managing other quality organizations in the pharmaceutical business provides me with the background necessary to meet our quality goals and deliver documents to our customers in a timely manner."

About Quorum Review
Quorum Review is an independent ethics review board that is fully accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP) and has been providing ethics review of drug and device trials since 1992. Quorum oversees research in accordance with U.S. and Canadian human research subject protection regulations, guidelines set forth by the International Committee on Harmonisation (ICH), and principles of the Belmont Report.    

Quorum's best-in-class service and support includes 3 protocol board meetings a week, daily amendment board meetings, 24 hour site review, 36 hour amendment review, and a secure web portal for online submissions, downloads and submission status review. Quorum can review studies in the US and Canada, review federally funded studies and has a specially designated Phase I study management team.